Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia

Go back to Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia
(NASDAQ: CRDF) Delayed: 0.94 +0.01 (1.08%)
Previous Close $0.93    52 Week High $ 
Open $0.95    52 Week Low $ 
Day High $0.97    P/E N/A 
Day Low $0.92    EPS $ 
Volume 427,786